[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 048″]
OIS Co-Chair Emmett Cunningham explains how Clarus will invest new $500m fund in ophthalmology and beyond.
Emmett T. Cunningham Jr., MD, PhD, MPH
Dr. Cunningham joined Clarus Ventures with 20+ years in the biomedical and biopharmaceutical sectors. Prior, Dr. Cunningham was the SVP, Medical Strategy at Eyetech Pharmaceuticals. He helped build and lead the team that developed and commercialized Macugen.